AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUN 2 - (NewsRx.com & NewsRx.net) -- An autoclaved Leishmania amazonensis vaccine plus BCG adjuvant was not effective against New World cutaneous leishmaniasis.
According to a study from the United States, "The safety, immunogenicity, and efficacy of two doses of an autoclaved-killed, whole cell Leishmania amazonensis vaccine (IFLA/BR/ 67/PH8) and BCG adjuvant (n=750) against cutaneous leishmaniasis (CL) was compared with placebo (n=756) in a randomized, placebo-controlled, blinded study. Systemic and local side effects were more frequent in the vaccine than placebo group. Leishmanin skin test (LST) conversion was greater in the vaccine than placebo group 2 months after the second vaccination dose (74.4% versus 14.7%; p=0.000001)."
"The 26-month incidence of confirmed CL (n=25) was similar between the vaccine (2.0%) and placebo groups (2.0% vs 1.3%; p>0.05)," reported Rodrigo X. Armijos and collaborators at the University of Texas-El Paso in the U.S. and the Universidad Central del Ecuador in Ecuador. "LST conversion was not associated with CL protection and the vaccine ...
Source: HighBeam Research, Leishmania amazonensis vaccine not effective against leishmaniasis.